ストックスクリーナーアプリを入手
106.14
1.67%
1.66
Ligand Pharmaceuticals Inc (LGND) 最新ニュース
Ligand Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Oppenheimer Maintains Rating and Raises Price Target for LGND | - GuruFocus
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Call Transcript - Insider Monkey
Oppenheimer Maintains Rating and Raises Price Target for LGND | LGND Stock News - GuruFocus
Oppenheimer Raises Price Target for Ligand (LGND) to $145 | LGND Stock News - GuruFocus
Oppenheimer Adjusts Ligand Pharmaceuticals Price Target to $145 From $142, Maintains Outperform Rating - marketscreener.com
Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Earnings call transcript: Ligand Pharmaceuticals beats Q1 2025 expectations - Investing.com
Ligand Pharmaceuticals Reports Strong Q1 2025 Revenue Growth - TipRanks
Ligand Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Ligand: Q1 Earnings Snapshot - Huron Daily Tribune
Earnings call transcript: Ligand Pharmaceuticals beats Q1 2025 expectations By Investing.com - Investing.com UK
Ligand Pharmaceuticals Q1 Core Adjusted Earnings, Revenue Increase; Shares Up Pre-Bell - marketscreener.com
Ligand (LGND) Upholds 2025 Financial Guidance | LGND Stock News - GuruFocus
Ligand Pharmaceuticals Reports Q1 Revenue of $45.3M, Beating Estimates; EPS Falls Short with $2.21 Loss - GuruFocus
Ligand (LGND) Exceeds Revenue Expectations with Strategic Moves - GuruFocus
Ligand (LGND) Exceeds Revenue Expectations with Strategic Moves | LGND Stock News - GuruFocus
Ligand Reports First Quarter 2025 Financial Results - GlobeNewswire
Earnings Flash (LGND) Ligand Pharmaceuticals Posts Q1 Revenue $45.3M, vs. FactSet Est of $38.7M - marketscreener.com
Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Report Preview: What To Look For - Yahoo Finance
Mariner LLC Purchases Shares of 2,574 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Deal Watch: Lilly Looks To Creyon For Oligonucleotides - insights.citeline.com
Ligand to Participate in May Investor Conferences - Stock Titan
Ligand Pharmaceuticals (LGND) Projected to Post Earnings on Thursday - Defense World
Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 49% Discount? - Yahoo Finance
Raymond James Financial Inc. Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Acquired by Wells Fargo & Company MN - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Sterling Capital Management LLC Has $59,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - American Banking and Market News
Ligand Q1 2025 Earnings Coming May 8: Key Financial Results and Business Updates Expected Pre-Market - Stock Titan
Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 - Yahoo Finance
Ligand unit Pelthos to merge with Channel Therapeutics - MSN
LGND: Pelthos To Become Public Company - Yahoo Finance
North Carolina adds new public company — it's hiring - The Business Journals
Bank of Montreal Can Grows Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
JPMorgan Chase & Co. Has $4.05 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Legal & General Group Plc Boosts Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Rating of “Buy” by Analysts - Defense World
Revisiting Ligand Pharmaceuticals, Ready To Accumulate If Shares Dip Below $100 - Seeking Alpha
Channel Therapeutics and Pelthos Therapeutics to Merge to Accelerate Launch of Zelsuvmi for Molluscum Contagiosum - Dermatology Times
Channel Therapeutics Sees Major Gains After Pharma Merger News - Finimize
Channel Therapeutics stock climbs on M&A deal (LGND:NASDAQ) - Seeking Alpha
Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated - MSN
Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics - marketscreener.com
Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated By Stocktwits - Investing.com India
Ligand’s Pelthos joins Channel - The Pharma Letter
Ligand subsidiaries, Chromocell Therapeutics to merge - TipRanks
Ligand, Channel Agree To Combine Pelthos, LNHC With CHRO Merger Sub - Nasdaq
Ligand Pharma Announces Merger to Enhance ZELSUVMI Sales - TipRanks
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel T - GuruFocus
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics - The Manila Times
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics | LGND Stock News - GuruFocus
Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics - marketscreener.com
Groundbreaking Skin Treatment Powers $50M Merger: First-Ever FDA-Approved Home Therapy for Molluscum - Stock Titan
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity - Benzinga
Alliancebernstein L.P. Sells 1,460 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals (NASDAQ:LGND) Upgraded at StockNews.com - Defense World
Wellington Management Group LLP Sells 1,085 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
0.81%
大文字化:
|
ボリューム (24 時間):